Citations (47)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Börje Ljungberg, Pernilla Sundqvist, Per Lindblad, Anders Kjellman, Andreas Thorstenson, Mikael Hellström, Britt-Inger Kröger Dahlin, Marcus Thomasson, Ulrika Harmenberg & Sven Lundstam. (2020) Survival advantage of upfront cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma compared with systemic and palliative treatments in a real-world setting. Scandinavian Journal of Urology 54:6, pages 487-492.
Read now
Read now
Farhood Iranparvar Alamdari, Torgny Rasmuson, Kjell Grankvist & Börje Ljungberg. (2007) Angiogenesis and other markers for prediction of survival in metastatic renal cell carcinoma. Scandinavian Journal of Urology and Nephrology 41:1, pages 5-9.
Read now
Read now
Articles from other publishers (45)
Kari Hemminki, Asta Försti, Akseli Hemminki, Börje Ljungberg & Otto Hemminki. (2021) Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden. PLOS ONE 16:6, pages e0253236.
Crossref
Crossref
Kyrollis Attalla, Stanley Weng, Martin H. Voss & A Ari Hakimi. (2020) Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma. Urologic Clinics of North America 47:3, pages 293-303.
Crossref
Crossref
Alberto De Gobbi, Mario Salvatore Mangano, Giandavide Cova, Claudio Lamon & Luigino Maccatrozzo. (2019) Testicular metastasis from renal cell carcinoma after nephrectomy and on tyrosine kinase inhibitors therapy: Case report and review. Urologia Journal 86:2, pages 96-98.
Crossref
Crossref
T. HiguchiN. YamamotoK. HayashiA. TakeuchiK. AbeY. TaniguchiS. KatoH. MurakamiH. Tsuchiya. (2018) Long-term patient survival after the surgical treatment of bone and soft-tissue metastases from renal cell carcinoma. The Bone & Joint Journal 100-B:9, pages 1241-1248.
Crossref
Crossref
Jonathan Mathias & Brian Rini. 2018. The American Cancer Society's Oncology in Practice. The American Cancer Society's Oncology in Practice
225
236
.
Nobuo Shinohara & Takashige Abe. (2015) Prognostic factors and risk classifications for patients with metastatic renal cell carcinoma. International Journal of Urology 22:10, pages 888-897.
Crossref
Crossref
Naruhiko Ikoma & Ara Vaporciyan. (2014) Sternal metastasis of renal cell carcinoma: The role of metastasectomy. The Journal of Thoracic and Cardiovascular Surgery 148:5, pages e230-e231.
Crossref
Crossref
Paolo Grassi, Elena Verzoni, Luca Porcu, Isabella Testa, Roberto Iacovelli, Valter Torri, Filippo de Braud & Giuseppe Procopio. (2014) Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factor. Future Oncology 10:8, pages 1361-1372.
Crossref
Crossref
Börje Ljungberg. (2012) The Role of Metastasectomy in Renal Cell Carcinoma in the Era of Targeted Therapy. Current Urology Reports 14:1, pages 19-25.
Crossref
Crossref
E. C. Hwang, I. S. Hwang, H. S. Yu, S.-O. Kim, S. I. Jung, J. E. Hwang, T. W. Kang, D. D. Kwon, K. Park & S. B. Ryu. (2012) Utility of Inflammation-based Prognostic Scoring in Patients Given Systemic Chemotherapy First-line for Advanced Inoperable Bladder Cancer. Japanese Journal of Clinical Oncology 42:10, pages 955-960.
Crossref
Crossref
Brian W. Cross, Timothy V. Johnson, Austin B. DeRosa, Kenneth Ogan, John G. Pattaras, Peter T. Nieh, Omer Kucuk, Wayne B. Harris & Viraj A. Master. (2012) Preoperative Erythrocyte Sedimentation Rate Independently Predicts Overall Survival in Localized Renal Cell Carcinoma following Radical Nephrectomy. International Journal of Surgical Oncology 2012, pages 1-6.
Crossref
Crossref
K.K.H. Aben, S. Heskamp, M.L. Janssen-Heijnen, E.L. Koldewijn, C.M. van Herpen, L.A. Kiemeney, E. Oosterwijk & D.J. van Spronsen. (2011) Better survival in patients with metastasised kidney cancer after nephrectomy: A population-based study in the Netherlands. European Journal of Cancer 47:13, pages 2023-2032.
Crossref
Crossref
Patricia A. Tang, Michael M. Vickers & Daniel Y.C. Heng. (2011) Clinical and Molecular Prognostic Factors in Renal Cell Carcinoma: What We Know So Far. Hematology/Oncology Clinics of North America 25:4, pages 871-891.
Crossref
Crossref
Igor Tsaur, Nicholas Obermüller, Dietger Jonas, Roman Blaheta, Eva Juengel, Ernst‐Heinrich Scheuermann, Heinz‐Georg Kachel, Athanasios Karalis & Michael Probst. (2010)
De novo
renal cell carcinoma of native and graft kidneys in renal transplant recipients
. BJU International 108:2, pages 229-234.
Crossref
Crossref
Robert C Flanigan, Anthony J Polcari & Cory M Hugen. (2011) Prognostic variables and nomograms for renal cell carcinoma. International Journal of Urology 18:1, pages 20-31.
Crossref
Crossref
Digant Gupta & Christopher G Lis. (2010) Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature. Nutrition Journal 9:1.
Crossref
Crossref
Emiliano Calvo, Pablo Maroto, Xavier García del Muro, Miguel Ángel Climent, José Luis González-Larriba, Emilio Esteban, Rafael López, Luis Paz-Ares, Joaquim Bellmunt & Daniel Castellano. (2010) Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma. Cancer and Metastasis Reviews 29:S1, pages 1-10.
Crossref
Crossref
G. Ploussard & A. de La Taille. (2010) Chirurgie du cancer du rein : quelle place à l’ère des thérapies ciblées?. Bulletin du Cancer 97:2, pages S91-S96.
Crossref
Crossref
Kevin G Kwan & Anil Kapoor. (2009) Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy. Current Opinion in Supportive and Palliative Care 3:3, pages 157-165.
Crossref
Crossref
Flavio L. Heldwein, Bernard Escudier, Gordon Smyth, Carlos A. V. Souto & Guy Vallancien. (2009) Metastatic renal cell carcinoma management. International braz j urol 35:3, pages 256-270.
Crossref
Crossref
Ronald M. Bukowski. (2009) Prognostic factors for survival in metastatic renal cell carcinoma. Cancer 115:S10, pages 2273-2281.
Crossref
Crossref
Anthony J Polcari, Alex Gorbonos, John E Milner & Robert C Flanigan. (2009) The role of cytoreductive nephrectomy in the era of molecular targeted therapy. International Journal of Urology 16:3, pages 227-233.
Crossref
Crossref
Börje Ljungberg, C. Damian Hanbury, A. Marcus Kuczyk, S. Axel Merseburger, F.A. Peter Mulders, Jean-Jacques Patard & C. Ioanel Sinescuf. (2009) Guía del carcinoma de células renales. Actas Urológicas Españolas 33:3, pages 270-279.
Crossref
Crossref
Bryan B. Voelzke & Robert C. Flanigan. 2008. Renal Cell Cancer. Renal Cell Cancer
257
278
.
Paul J. Elson. 2008. Clinical Management of Renal Tumors. Clinical Management of Renal Tumors
307
322
.
Börje Ljungberg, Damian C. Hanbury, Marcus A. Kuczyk, Axel S. Merseburger, Peter F.A. Mulders, Jean-Jacques Patard & Ioanel C. Sinescu. (2007) Renal Cell Carcinoma Guideline. European Urology 51:6, pages 1502-1510.
Crossref
Crossref
T.K. Choueiri, B.I. Rini, J.A. Garcia, R.C. Baz, R.M. Abou-Jawde, S.G. Thakkar, P. Elson, T.M. Mekhail, M. Zhou & R.M. Bukowski. (2007) Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma. Annals of Oncology 18:2, pages 249-255.
Crossref
Crossref
Sang Eun Lee, Seok-Soo Byun, June Hyun Han, Byung Kyu Han & Sung Kyu Hong. (2006) Prognostic significance of common preoperative laboratory variables in clear cell renal cell carcinoma. BJU International 98:6, pages 1228-1232.
Crossref
Crossref
Catherine A. Hauser, Martin R. Stockler & Martin H. N. Tattersall. (2006) Prognostic factors in patients with recently diagnosed incurable cancer: a systematic review. Supportive Care in Cancer 14:10, pages 999-1011.
Crossref
Crossref
Andrew S. Artz, Masha Kocherginsky & Koen Besien. (2006) Order of patient entry influences outcome for metastatic renal cell cancer after non-myeloablative allogeneic stem cell transplantation. British Journal of Haematology 132:6, pages 747-754.
Crossref
Crossref
Shomik Sengupta, Christine M. Lohse, John C. Cheville, Bradley C. Leibovich, R. Houston Thompson, W. Scott Webster, Igor Frank, Horst Zincke, Michael L. Blute & Eugene D. Kwon. (2006) The preoperative erythrocyte sedimentation rate is an independent prognostic factor in renal cell carcinoma. Cancer 106:2, pages 304-312.
Crossref
Crossref
Young Kyun KimSun Il KimSe Joong Kim. (2006) Significance of Erythrocyte Sedimentation Rate and C-reactive Protein as Predictive Factors for Prognosis in Non-metastatic Renal Cell Carcinoma. Korean Journal of Urology 47:10, pages 1059.
Crossref
Crossref
Shomik Sengupta, Bradley C Leibovich, Michael L Blute & Horst Zincke. (2005) Surgery for metastatic renal cell cancer. World Journal of Urology 23:3, pages 155-160.
Crossref
Crossref
A S Artz, K Van Besien, T Zimmerman, T F Gajewski, B I Rini, H S Hu, W M Stadler & N J Vogelzang. (2004) Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience. Bone Marrow Transplantation 35:3, pages 253-260.
Crossref
Crossref
Geoff Delaney, Susannah Jacob & Michael Barton. (2005) Estimating the optimal external‐beam radiotherapy utilization rate for genitourinary malignancies. Cancer 103:3, pages 462-473.
Crossref
Crossref
Jan Lehmann, Margitta Retz, Nils Nürnberg, Uta Schnöckel, Uta Raffenberg, Matthias Krams, Udo Kellner, Stefan Siemer, Klaus Weichert‐Jacobsen & Michael Stöckle. (2004) The superior prognostic value of humoral factors compared with molecular proliferation markers in renal cell carcinoma. Cancer 101:7, pages 1552-1562.
Crossref
Crossref
B. Ljungberg. (2016) Prognostic Factors in Renal Cell Carcinoma. Scandinavian Journal of Surgery 93:2, pages 118-125.
Crossref
Crossref
C. Beisland & H. O. Beisland. (2016) Natural and Clinical Course of Renal Cell Carcinoma — Better Prospect for the Patients. Scandinavian Journal of Surgery 93:2, pages 97-101.
Crossref
Crossref
Bradley C. Leibovich, Ken‐ryu Han, Matthew H. T. Bui, Allan J. Pantuck, Frederick J. Dorey, Robert A. Figlin & Arie Belldegrun. (2003) Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma. Cancer 98:12, pages 2566-2575.
Crossref
Crossref
Ziya Kirkali & Murat Lekili. (2003) Renal cell carcinoma: new prognostic factors?. Current Opinion in Urology 13:6, pages 433-438.
Crossref
Crossref
Kevin P. Stiles, Michael J. Moffatt, Lawrence Y. Agodoa, S. John Swanson & Kevin C. Abbott. (2003) Renal cell carcinoma as a cause of end-stage renal disease in the United States: Patient characteristics and survival. Kidney International 64:1, pages 247-253.
Crossref
Crossref
Kristina Hotakainen, Börge Ljungberg, Caj Haglund, Stig Nordling, Annukka Paju & Ulf‐Hakan Stenman. (2003) Expression of the free β‐subunit of human chorionic gonadotropin in renal cell carcinoma: Prognostic study on tissue and serum. International Journal of Cancer 104:5, pages 631-635.
Crossref
Crossref
Ken-Ryu Han, Allan J Pantuck, Matthew H.T Bui, Oleg Shvarts, Danielo G Freitas, Amnon Zisman, Bradley C Leibovich, Frederick J Dorey, Barbara J Gitlitz, Robert A Figlin & Arie S Belldegrun. (2003) Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology 61:2, pages 314-319.
Crossref
Crossref
D. Leibovici, A. Sella, I. Y. Siegel & A. Zisman. 2003. Kidney Cancer. Kidney Cancer
53
68
.
Kalevi Juhani Pulkkanen, Johanna M Laukkanen, Jonas Fuxe, Mikko I Kettunen, Marko Rehn, Jani M Kannasto, Jyrki J Parkkinen, Risto A Kauppinen, Ralf F Pettersson & Seppo Yla-Herttuala. (2002) The combination of HSV-tk and endostatin gene therapy eradicates orthotopic human renal cell carcinomas in nude mice. Cancer Gene Therapy 9:11, pages 908-916.
Crossref
Crossref